WAYNE, Pa., July 12, 2016 /PRNewswire/ -- Ryan &
Maniskas, LLP is investigating potential claims against the board
of directors of Sagent Pharmaceuticals, Inc. ("Sagent" or the
"Company") (NASDAQ: SGNT) concerning possible breaches of fiduciary
duty and other violations of law related to the Company's efforts
to sell the Company to Nichi-Iko Pharmaceutical Co., Ltd in a
transaction valued at approximately $736
million.
If you own shares of Sagent and would like to learn more about
this class action or if you wish to discuss these matters and have
any questions concerning this announcement or your rights, contact
Richard A. Maniskas, Esquire
toll-free at (877) 316-3218 or to sign up online, visit:
www.rmclasslaw.com/cases/sgnt. You may also email Mr. Maniskas at
rmaniskas@rmclasslaw.com.
Under the terms of the agreement, shareholders of Sagent will
receive $21.75 in cash for each share
of Sagent common stock.
Our investigation concerns possible breaches of fiduciary duty
and other violations of state law by the Board of Directors of
Sagent or not acting in the Company's shareholders' best interests
in connection with the sale process.
Ryan & Maniskas, LLP is a national shareholder litigation
firm. Ryan & Maniskas, LLP is devoted to protecting the
interests of individual and institutional investors in shareholder
actions in state and federal courts nationwide. To learn more
about the class action process, please visit:
www.rmclasslaw.com.
CONTACT: Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old
Eagle School Rd., Suite 311
Wayne, PA 19087
877-316-3218
www.rmclasslaw.com/cases/sgnt
rmaniskas@rmclasslaw.com
Logo -
http://photos.prnewswire.com/prnh/20121112/MM11729LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ryan--maniskas-llp-announces-investigation-of-sagent-pharmaceuticals-inc-300297339.html
SOURCE Ryan & Maniskas, LLP